We’re getting closer to the finish line! It was announced early this morning that Vertex submitted a New Drug Application to the FDA! Vertex also submitted for a priority review, which, if accepted, “would shorten the FDA’s review of the NDA to eight months from the time of submission, versus a standard review timeline of...
Continue reading...
Full disclosure, I had a healthy dose of Propofol about 3 hours ago, so what follows is, well… the best I can do. If you visited my page yesterday, you know that I had my first ever colonoscopy today. To recap, people with CF need to get colonoscopies younger than the general population because there...
Continue reading...
Did you know that when you have CF, you’re due for a colonoscopy much earlier than the general population? Kind of shitty, right? The reason that’s the case is because there’s an increased risk for colorectal cancer in the CF population. I know… I know… it sort of feels like we keep losing the lottery...
Continue reading...
It’s been awhile since I’ve blogged! My move to grad school is coming (14 days, but who is counting?), so my mind has been elsewhere, but today, I’m back! Darcy sent me a link this morning to a blog post written by Tiffany Jenkins. She is the author of a popular new book that she...
Continue reading...
Amy is back with the final installment of her miniseries Coverage Tips for Costly Drugs. Today she is going to take you through the alternative cost assistance programs, which may apply to different populations. It’s important to note that what is discussed below may not apply to you depending on your coverage situation. It is...
Continue reading...
Amy is back with the second installment of her miniseries Coverage Tips for Costly Drugs. Today she is going to take you through the Medicare landscape, which as you will see below can be a bit tricky. It’s important to note that what is discussed below may not apply to you depending on your coverage...
Continue reading...
Amy, who generously penned our Drug Development Wednesday series, is back to discuss coverage options and payment strategies in the United States. This guest column will include three blogs and discuss different ways people may face easy access to medications or challenging and costly hurdles. It’s important to note that what is discussed below may...
Continue reading...
